Drug Trial Radar · NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
Jul 31, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.
LenalidomideDrug
Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
TocilizumabDrug
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
IberdomideDrug
Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
DexamethasoneDrug
Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Percentage of Participants with Adverse Events (AEs)Time frame: Baseline up to approximately 5 years
- Stage 2: Objective Response Rate (ORR)Time frame: Baseline up to approximately 5 years
- Stage 2: Complete Response (CR) or Stringent Complete Response (sCR) RateTime frame: Baseline up to approximately 5 years
- Stage 2: Rate of Very Good Partial Response (VGPR) or BetterTime frame: Baseline up to approximately 5 years
- Stage 2: Progression-free Survival (PFS)Time frame: Baseline up to approximately 5 years
- Stage 2: Overall Survival (OS)Time frame: Baseline up to approximately 5 years
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Prince of Wales Hospital
Randwick, New South Wales, Australia · Recruiting
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
CHU Lyon Sud - Service Hématologie
Pierre-Bénite, France · Recruiting
IUCT Oncopole
Toulouse, France · Recruiting
Hopital Bretonneau
Tours, France · Recruiting
IGR
Villejuif, France · Withdrawn
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
Hamburg, Germany · Recruiting
Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie
Leipzig, Germany · Recruiting
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland · Recruiting
Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, Poland · Recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, Poland · Withdrawn
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.